Codexis Announces New Employment Inducement Grants
Codexis (NASDAQ: CDXS), a leading enzyme engineering company, has announced the approval of equity grants for three new employees. These grants, approved by the Compensation Committee of Codexis' Board of Directors, include:
1. Options to purchase 4,950 shares of Codexis common stock
2. 8,125 restricted stock units (RSUs)
The stock options have an exercise price equal to the closing price of Codexis' common stock on the grant date. They vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. The RSUs will vest in equal annual installments over three years. Both are subject to continued employment. This announcement is in compliance with Nasdaq Listing Rule 5635(c)4.
Codexis (NASDAQ: CDXS), un'azienda leader nell'ingegneria degli enzimi, ha annunciato l'approvazione di assegnazioni di azioni per tre nuovi dipendenti. Queste assegnazioni, approvate dal Comitato Compensi del Consiglio di Amministrazione di Codexis, includono:
1. Opzioni per acquistare 4.950 azioni ordinarie di Codexis
2. 8.125 unità azionarie vincolate (RSUs)
Le opzioni azionarie hanno un prezzo di esercizio pari al prezzo di chiusura delle azioni ordinarie di Codexis alla data di assegnazione. Si maturano in quattro anni, con il 25% che matura al primo anniversario e il resto che matura mensilmente da quel momento in poi. Le RSUs matureranno in rate annuali uguali nel corso di tre anni. Entrambi sono soggetti a un impiego continuato. Questo annuncio è conforme alla Regola di Quotazione Nasdaq 5635(c)4.
Codexis (NASDAQ: CDXS), una empresa líder en ingeniería de enzimas, ha anunciado la aprobación de otorgamientos de acciones para tres nuevos empleados. Estos otorgamientos, aprobados por el Comité de Compensación de la Junta Directiva de Codexis, incluyen:
1. Opciones para comprar 4,950 acciones comunes de Codexis
2. 8,125 unidades de acciones restringidas (RSUs)
Las opciones sobre acciones tienen un precio de ejercicio igual al precio de cierre de las acciones comunes de Codexis en la fecha de concesión. Se consolidan en cuatro años, con el 25% consolidándose en el primer aniversario y el resto consolidándose mensualmente a partir de entonces. Las RSUs se consolidarán en cuotas anuales iguales durante tres años. Ambos están sujetos a empleo continuado. Este anuncio cumple con la Regla de Cotización Nasdaq 5635(c)4.
코덱시스(Codexis)(NASDAQ: CDXS), 선도적인 효소 공학 회사가 세 명의 신입 직원에게 주식 보상 승인을 발표했습니다. 이 보상은 코덱시스 이사회의 보상위원회에 의해 승인되었으며 다음을 포함합니다:
1. 코덱시스 보통주 4,950주 매수 옵션
2. 8,125 제한주식단위 (RSUs)
주식 매수 옵션의 행사 가격은 보상 날짜의 코덱시스 보통주의 종가와 동일합니다. 이들은 4년에 걸쳐 만료되며, 첫 번째 기념일에 25%가 만료되고 이후 매달 나머지가 만료됩니다. RSUs는 3년 동안 동일한 연간 할부로 만료됩니다. 두 가지 모두 지속적인 고용에 따라 다릅니다. 이 발표는 나스닥 상장 규정 5635(c)4를 준수합니다.
Codexis (NASDAQ: CDXS), une entreprise leader dans l'ingénierie des enzymes, a annoncé l'approbation des attributions d'actions pour trois nouveaux employés. Ces attributions, approuvées par le Comité de Rémunération du Conseil d'Administration de Codexis, comprennent :
1. Des options pour acheter 4.950 actions ordinaires de Codexis
2. 8.125 unités d'actions restreintes (RSUs)
Les options d'achat d'actions ont un prix d'exercice équivalent au prix de clôture des actions ordinaires de Codexis à la date d'attribution. Elles s'acquièrent sur une période de quatre ans, avec 25% d'acquisition lors du premier anniversaire et le reste s'acquérant mensuellement par la suite. Les RSUs s'acquerront en versements annuels égaux sur trois ans. Les deux sont soumis à un emploi continu. Cet annonce est conforme à la règle 5635(c)4 de la cote Nasdaq.
Codexis (NASDAQ: CDXS), ein führendes Unternehmen im Bereich der Enzymtechnik, hat die Genehmigung von Aktienzuteilungen für drei neue Mitarbeiter bekannt gegeben. Diese Zuteilungen, die vom Vergütungsausschuss des Vorstands von Codexis genehmigt wurden, beinhalten:
1. Optionen zum Kauf von 4.950 Aktien der Codexis-Stammaktien
2. 8.125 beschränkte Aktieneinheiten (RSUs)
Die Aktienoptionen haben einen Ausübungspreis, der dem Schlusskurs der Codexis-Stammaktien am Zuteilungsdatum entspricht. Sie werden über einen Zeitraum von vier Jahren unangetastet, wobei 25% am ersten Jubiläum und der Rest anschließend monatlich ausbezahlt wird. Die RSUs werden in gleichen jährlichen Raten über drei Jahre fällig. Beide sind an eine fortgesetzte Beschäftigung gebunden. Diese Ankündigung erfolgt gemäß der Nasdaq-Listing-Regel 5635(c)4.
- Codexis is attracting new talent with competitive equity compensation packages
- The company is transparent about its employee compensation practices, complying with Nasdaq listing rules
- None.
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 4,950 shares of Codexis common stock and (ii) 8,125 restricted stock units (RSUs) as inducement awards under the company’s 2024 Inducement Plan.
The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to each employee’s continued service with Codexis through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to each employee’s continued service with Codexis through the applicable vesting dates.
Codexis is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
What type of equity grants did Codexis (CDXS) announce for new employees?
How do the stock options granted by Codexis (CDXS) vest?
What is the vesting schedule for the RSUs granted by Codexis (CDXS)?
Why did Codexis (CDXS) make this announcement about employee equity grants?
